Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

		Substitute for	torm 1449	A/PTO	C m	plete if Known	RECE
	6	STA	₿ ÆME	TION DISCLOSURE NT BY APPLICANT any sheets as necessary)	Application Number	10/044,538	SEP 25
· [.	. \	SEP 23 ZUUL		any chocke ao hicoccany)	Filing Date	January 10, 2	CH CENTER
	10		æ/		First Named Inventor	Abraham J. [
ı	12	TE TRADEN			Group Art Unit	1636	
L		& TRAUS			Examiner Name		
S	Sheet	1	of	2	Attorney Docket Number	PG 100	

			U.S. PATENT DOCUM	IENTS		
Initials* No.1		US Patent Document Number Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevan Passages or Relevant Figures Appear	
(3-K		3,225,012	Black, et al.	12-21-1965		
i		4,146,515	Buikema et al.	03-27-1979		
		5,312,967	Kieley, et al.	05-17-1994		
		5,329,044	Kieley, et al.	07-12-1994		
		5,434,233	Kieley, et al.	07-18-1995		
		5,473,035	Kieley, et al.	12-05-1995		
(-K		5,833,230	Nakagawa, et al.	11-10-1998		

FOREIGN PATENT DOCUMENTS								
Examiner Cite Foreign Patent Document No.1			Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵			
		Office.3	Number⁴	Kind Code ⁵ (if known)			J 11	
		POT	WO-95/30020		Immuno-Designed Molecules-	12-09-1995		
GL		PCT	WO 97/46223		Genzyme Corporation	12-11-1997		
1		PCT	WO 98/27209		Emory University	06-25-1998		
		PCT	WO 01/07486		Polygene, Ltd.	02-01-2001		
GY		EP	0 370 810		Nippon Oil and Fats Co.	11-23-1989		
		1						

Examine Signature	Gikny	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

RECEIVED

SEP 2 7 2002

TECH CENTER 1600/2900

+

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

lease type a plus sign (+) inside this box →	+

	PTO/SB/08A (10-96
Approved for	use through 10/31/99. OMB 0651-0031
Patent and Trademark Office:	: U.S. DEPARTMENT OF COMMERCE

	the state of the s			E OOMMENOE	
	Under the Paperwork Reduction Act of 1995, no persons are required to respond to	a collection of information unless it conta	ains a valid OMB control number	-RECA	
	Substitute for form 1449A/PTO		Complete if Known	SED	IVE
	INFORMATION DISCLOSURE	Application Number	10/044,538	3EP 23	2002
•	(use, as many sheets as necessary)			TECH CENTER	-002 1600/20
•	SEP 2 3 2002 E	Filing Date	January 10, 2002		-0/20
	SEP 10 10 E/	First Named Inventor	Abraham J. Domb		
	St. WET	Group Art Unit	1636		
	TENT O TO A DEMAN	Examiner Name			
	Sheet of 2	Attorney Docket Number	PG 100		

		OTHER ART NON PATENT LITERATURE DOCUMENTS	Τ		
Examiner's Initials*					
GK		BYK & SCHERMAN Exp. Opin. Ther. 8(9): 1125-1141 (1998).			
		DOMB, et al., "Polymers in gene therapy," in <u>Frontiers in Biological Polymer Applications</u> (Ottenbrite, ed.) Technomic: Lancaster, Vol. 2, pp. 1-16 (1999).			
		KIELY, et al., "Hydroxylated nylons based on unprotected esterified D-glucaric acid by simple condensation reactions," J. Am. Chem. Soc. 116: 571-578 (1994).			
		LEDLEY, "Nonviral gene therapy: The promise of genes as pharmaceutical products," <i>Human Gene Therapy</i> 6: 1129-1144 (1995).			
		LEE, et al., "Self aggregates of hydrophobically modified chitosan for DNA delivery," <i>Proceed Intl. Symp. Control. Rel. Boiact. Matter</i> 24: 651-652 (1997).			
		MAO, et al., "DNA-chitosan nanospheres: derivitization and storage stability," Proc. Intl. Symp. Control Rel. Bioact. Matter 24: 671-672 (1997).			
		RICHARDSON, et al., "Evaluation of highly purified chitosan as a potential gene delivery vector," Proceed Intl. Symp. Control Rel. Bioact. Matter 24: 649-650 (1997).			
		TAKAKURA, et al., "Control of pharmaceutical properties of soybean tyrosine inhibitor by conjugation with dextran 1: synthesis and characterization," <i>J. Pharm. Sci.</i> 78(2): 117-121 (1999).			
		TRECO & SELDEN, "Non viral gene therapy," <i>Molec. Med. Today</i> 1(7):299-348 (1995).			
		WALSH, et al., "Combination of drug and gene delivery by gelatin nanospheres for the treatment of cystic fibrosis," Proc. Intl. Sym. Control. Rel. Bioact. Mater. 24: 75-76 (1997).			
GK		YAMAOKA, et al., "Effect of cation content of polycation-type gene carriers on in vitro gene transfer," Chemistry Letters, 1171-1172 (1998).			

Examiner's Signature Date, Considered 4/5/93	 		
	 G.KTIL	- 4/5/03	,

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SEP 2 7 2002

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language